Symbols / MRKR $1.48 +12.12% Marker Therapeutics, Inc.
MRKR Chart
About
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 19.15M |
| Enterprise Value | 5.94M | Income | -12.16M | Sales | 3.55M |
| Book/sh | 1.01 | Cash/sh | 0.96 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | — | Forward P/E | -7.79 | PEG | — |
| P/S | 5.40 | P/B | 1.47 | P/C | — |
| EV/EBITDA | — | EV/Sales | 1.68 | Quick Ratio | 7.67 |
| Current Ratio | 8.39 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.79 | EPS next Y | -0.19 | EPS Growth | — |
| Revenue Growth | -51.00% | Earnings | 2026-03-18 17:00 | ROA | -37.83% |
| ROE | -68.81% | ROIC | — | Gross Margin | -232.68% |
| Oper. Margin | -170.74% | Profit Margin | 0.00% | Shs Outstand | 12.94M |
| Shs Float | 13.81M | Short Float | 4.43% | Short Ratio | 5.05 |
| Short Interest | — | 52W High | 4.07 | 52W Low | 0.81 |
| Beta | 1.47 | Avg Volume | 276.76K | Volume | 190.23K |
| Target Price | $7.87 | Recom | None | Prev Close | $1.32 |
| Price | $1.48 | Change | 12.12% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2025-04-01 | reit | WBB Securities | Strong Buy → Strong Buy | $13 |
| 2025-03-05 | init | Canaccord Genuity | — → Buy | $8 |
| 2024-04-30 | init | Ladenburg Thalmann | — → Buy | $11 |
- Marker Therapeutics, Inc. (MRKR) stock price, news, quote and history - Yahoo Finance UK Sat, 04 Apr 2026 07
- 66% lymphoma response rate gives Marker a new data catalyst for 2026 - Stock Titan Wed, 18 Mar 2026 07
- H.C. Wainwright Maintains Marker Therapeutics(MRKR.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛 Mon, 06 Apr 2026 07
- Marker Therapeutics, Inc. (MRKR) reports Q4 loss, tops revenue estimates - MSN hu, 19 Mar 2026 04
- MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Yahoo Finance Wed, 21 Jan 2026 08
- Would You Still Hold Marker Therapeutics Stock If It Fell Another 30%? - Trefis Sun, 21 Dec 2025 08
- Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - simplywall.st Mon, 12 Jan 2026 08
- Marker Therapeutics stock maintains Buy rating at H.C. Wainwright - Investing.com ue, 06 Jan 2026 08
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results - GlobeNewswire Wed, 18 Mar 2026 07
- Marker Therapeutics (NASDAQ: MRKR) reports 2025 loss and cash runway into late 2026 - Stock Titan Wed, 18 Mar 2026 07
- Brookline Capital raises Marker Therapeutics stock price target to $5.60 - Investing.com Mon, 05 Jan 2026 08
- Marker Therapeutics Second Quarter 2025 Earnings: Beats Expectations - simplywall.st Sat, 16 Aug 2025 07
- MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance Wed, 07 Jan 2026 08
- Here's Why Marker Therapeutics (NASDAQ:MRKR) Must Use Its Cash Wisely - Yahoo Finance hu, 18 Dec 2025 08
- Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study - Yahoo Finance Wed, 27 Aug 2025 07
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
3.31
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
3.31
|
0.00
|
| Operating Expense |
|
12.44
+11.86%
|
11.12
-23.75%
|
14.58
-26.32%
|
19.79
|
| Research And Development |
|
11.80
-12.39%
|
13.47
+29.29%
|
10.42
-12.96%
|
11.97
|
| Selling General And Administration |
|
4.18
-1.34%
|
4.24
-43.26%
|
7.48
-34.05%
|
11.34
|
| General And Administrative Expense |
|
4.18
-1.34%
|
4.24
-43.26%
|
7.48
-34.05%
|
11.34
|
| Other Gand A |
|
4.18
-1.34%
|
4.24
-43.26%
|
7.48
-34.05%
|
11.34
|
| Other Operating Expenses |
|
-3.55
+46.19%
|
-6.59
-99.06%
|
-3.31
+5.76%
|
-3.51
|
| Total Expenses |
|
12.44
+11.86%
|
11.12
-23.75%
|
14.58
-26.32%
|
19.79
|
| Operating Income |
|
-12.44
-11.86%
|
-11.12
+1.35%
|
-11.27
+43.05%
|
-19.79
|
| Total Operating Income As Reported |
|
-12.89
-15.94%
|
-11.12
+23.75%
|
-14.58
+26.32%
|
-19.79
|
| EBITDA |
|
-12.44
-11.86%
|
-11.12
+1.35%
|
-11.27
+43.05%
|
-19.79
|
| Normalized EBITDA |
|
-11.98
-7.79%
|
-11.12
+1.35%
|
-11.27
+43.05%
|
-19.79
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
3.68
|
| EBIT |
|
-12.44
-11.86%
|
-11.12
+1.35%
|
-11.27
+43.05%
|
-19.79
|
| Total Unusual Items |
|
-0.45
|
0.00
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
-0.45
|
0.00
|
—
|
—
|
| Special Income Charges |
|
-0.45
|
0.00
|
—
|
—
|
| Other Special Charges |
|
0.45
|
—
|
—
|
—
|
| Net Income |
|
-12.16
-13.35%
|
-10.73
-30.28%
|
-8.24
+72.48%
|
-29.93
|
| Pretax Income |
|
-12.18
-14.02%
|
-10.68
+0.46%
|
-10.73
+45.74%
|
-19.78
|
| Net Non Operating Interest Income Expense |
|
0.59
+35.97%
|
0.44
-18.95%
|
0.54
+117.35%
|
0.25
|
| Net Interest Income |
|
0.59
+35.97%
|
0.44
-18.95%
|
0.54
+117.35%
|
0.25
|
| Interest Income Non Operating |
|
0.59
+35.97%
|
0.44
-18.95%
|
0.54
+117.35%
|
0.25
|
| Interest Income |
|
0.59
+35.97%
|
0.44
-18.95%
|
0.54
+117.35%
|
0.25
|
| Other Income Expense |
|
-0.34
|
—
|
—
|
-0.23
|
| Other Non Operating Income Expenses |
|
0.12
|
—
|
—
|
-0.23
|
| Tax Provision |
|
-0.02
-130.34%
|
0.05
+1259.27%
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.16
-13.35%
|
-10.73
-30.28%
|
-8.24
+72.48%
|
-29.93
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.16
-13.35%
|
-10.73
+23.60%
|
-14.05
+28.97%
|
-19.78
|
| Net Income From Continuing And Discontinued Operation |
|
-12.16
-13.35%
|
-10.73
-30.28%
|
-8.24
+72.48%
|
-29.93
|
| Net Income Continuous Operations |
|
-12.16
-13.35%
|
-10.73
+23.60%
|
-14.05
+28.97%
|
-19.78
|
| Net Income Discontinuous Operations |
|
—
|
0.00
-100.00%
|
5.81
+157.21%
|
-10.15
|
| Normalized Income |
|
-11.71
-9.12%
|
-10.73
+23.60%
|
-14.05
+28.97%
|
-19.78
|
| Net Income Common Stockholders |
|
-12.16
-13.35%
|
-10.73
-30.28%
|
-8.24
+72.48%
|
-29.93
|
| Diluted EPS |
|
-0.79
+33.61%
|
-1.19
-26.60%
|
-0.94
+73.74%
|
-3.58
|
| Basic EPS |
|
-0.79
+33.61%
|
-1.19
-26.60%
|
-0.94
+73.74%
|
-3.58
|
| Basic Average Shares |
|
15.31
+70.49%
|
8.98
+1.94%
|
8.81
+5.49%
|
8.35
|
| Diluted Average Shares |
|
15.31
+70.49%
|
8.98
+1.94%
|
8.81
+5.49%
|
8.35
|
| Diluted NI Availto Com Stockholders |
|
-12.16
-13.35%
|
-10.73
-30.28%
|
-8.24
+72.48%
|
-29.93
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
19.07
-13.40%
|
22.02
+28.58%
|
17.13
-50.24%
|
34.42
|
| Current Assets |
|
19.07
-13.40%
|
22.02
+28.58%
|
17.13
+3.06%
|
16.62
|
| Cash Cash Equivalents And Short Term Investments |
|
16.07
-16.28%
|
19.19
+27.01%
|
15.11
+28.26%
|
11.78
|
| Cash And Cash Equivalents |
|
16.07
-16.28%
|
19.19
+27.01%
|
15.11
+28.26%
|
11.78
|
| Receivables |
|
1.37
-41.65%
|
2.35
+128.32%
|
1.03
-57.21%
|
2.40
|
| Other Receivables |
|
1.37
-41.65%
|
2.35
+128.32%
|
1.03
-57.21%
|
2.40
|
| Prepaid Assets |
|
0.66
+36.19%
|
0.48
-51.05%
|
0.99
-46.57%
|
1.85
|
| Restricted Cash |
|
0.97
|
0.00
|
—
|
0.00
|
| Assets Held For Sale Current |
|
—
|
—
|
0.00
-100.00%
|
0.59
|
| Total Non Current Assets |
|
0.00
|
0.00
|
0.00
-100.00%
|
17.80
|
| Net PPE |
|
—
|
—
|
—
|
17.80
|
| Gross PPE |
|
—
|
—
|
—
|
23.08
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
-5.27
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
1.82
|
| Construction In Progress |
|
—
|
—
|
—
|
0.00
|
| Other Properties |
|
—
|
—
|
—
|
17.30
|
| Leases |
|
—
|
—
|
—
|
3.95
|
| Other Non Current Assets |
|
—
|
—
|
—
|
17.80
|
| Total Liabilities Net Minority Interest |
|
2.27
-34.36%
|
3.46
+12.67%
|
3.07
-79.25%
|
14.82
|
| Current Liabilities |
|
2.27
-34.36%
|
3.46
+12.67%
|
3.07
-60.49%
|
7.78
|
| Payables And Accrued Expenses |
|
1.21
-64.11%
|
3.38
+11.94%
|
3.02
+70.39%
|
1.77
|
| Payables |
|
0.85
-70.56%
|
2.88
+14.82%
|
2.51
+127.94%
|
1.10
|
| Accounts Payable |
|
0.79
-25.57%
|
1.07
+10.97%
|
0.96
-12.72%
|
1.10
|
| Current Accrued Expenses |
|
0.36
-26.72%
|
0.50
-2.24%
|
0.51
-24.18%
|
0.67
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.09
+0.85%
|
0.09
+51.49%
|
0.06
-92.40%
|
0.75
|
| Total Tax Payable |
|
0.05
-47.76%
|
0.10
-52.24%
|
0.22
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.58
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
0.58
|
| Current Deferred Liabilities |
|
0.97
|
0.00
|
—
|
2.50
|
| Current Deferred Revenue |
|
0.97
|
0.00
|
—
|
2.50
|
| Other Current Liabilities |
|
—
|
0.00
+394.30%
|
0.00
-100.00%
|
5.26
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
7.04
|
| Liabilities Heldfor Sale Non Current |
|
—
|
—
|
0.00
-100.00%
|
7.04
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
7.04
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
7.04
|
| Stockholders Equity |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Common Stock Equity |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Capital Stock |
|
0.02
+55.70%
|
0.01
+20.44%
|
0.01
+5.77%
|
0.01
|
| Common Stock |
|
0.02
+55.70%
|
0.01
+20.44%
|
0.01
+5.77%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
16.67
+55.69%
|
10.71
+20.33%
|
8.90
+5.95%
|
8.40
|
| Ordinary Shares Number |
|
16.67
+55.69%
|
10.71
+20.33%
|
8.90
+5.95%
|
8.40
|
| Additional Paid In Capital |
|
475.96
+2.23%
|
465.56
+3.38%
|
450.33
+0.60%
|
447.64
|
| Retained Earnings |
|
-459.18
-2.72%
|
-447.02
-2.46%
|
-436.29
-1.92%
|
-428.05
|
| Total Equity Gross Minority Interest |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Total Capitalization |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Working Capital |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
+59.01%
|
8.84
|
| Invested Capital |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Total Debt |
|
—
|
—
|
—
|
7.62
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
7.62
|
| Net Tangible Assets |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Tangible Book Value |
|
16.80
-9.49%
|
18.56
+32.06%
|
14.05
-28.31%
|
19.60
|
| Dueto Related Parties Current |
|
0.00
-100.00%
|
1.71
+28.64%
|
1.33
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-12.01
-10.12%
|
-10.91
+33.64%
|
-16.44
+39.05%
|
-26.97
|
| Cash Flow From Continuing Operating Activities |
|
-12.01
-10.12%
|
-10.91
-5.50%
|
-10.34
+51.93%
|
-21.51
|
| Cash From Discontinued Operating Activities |
|
—
|
0.00
+100.00%
|
-6.10
-11.73%
|
-5.46
|
| Net Income From Continuing Operations |
|
-12.16
-13.35%
|
-10.73
+23.60%
|
-14.05
+28.97%
|
-19.78
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
3.68
|
| Depreciation |
|
—
|
—
|
—
|
3.68
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
3.68
|
| Other Non Cash Items |
|
—
|
—
|
—
|
-0.28
|
| Stock Based Compensation |
|
0.54
+118.63%
|
0.25
-71.35%
|
0.86
-74.03%
|
3.30
|
| Operating Gains Losses |
|
—
|
—
|
—
|
0.03
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.03
|
| Change In Working Capital |
|
-0.39
+8.68%
|
-0.42
-114.93%
|
2.85
+159.76%
|
-4.76
|
| Change In Receivables |
|
0.98
+174.10%
|
-1.32
-195.98%
|
1.37
+157.22%
|
-2.40
|
| Change In Prepaid Assets |
|
-0.18
-134.70%
|
0.50
-41.42%
|
0.86
+726.82%
|
0.10
|
| Change In Payables And Accrued Expense |
|
-2.17
-655.71%
|
0.39
-36.26%
|
0.61
+146.32%
|
-1.32
|
| Change In Payable |
|
-2.17
-655.71%
|
0.39
-36.26%
|
0.61
|
—
|
| Change In Account Payable |
|
-0.45
-5288.56%
|
0.01
+101.22%
|
-0.72
|
—
|
| Change In Other Working Capital |
|
0.97
|
—
|
—
|
-1.15
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
-0.51
|
| Investing Cash Flow |
|
—
|
0.00
-100.00%
|
18.66
+477.42%
|
-4.95
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
—
|
-4.95
|
| Cash From Discontinued Investing Activities |
|
—
|
0.00
-100.00%
|
18.66
+477.42%
|
-4.95
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
-4.95
|
| Purchase Of PPE |
|
—
|
—
|
—
|
-4.95
|
| Capital Expenditure |
|
—
|
—
|
—
|
-4.95
|
| Financing Cash Flow |
|
9.86
-34.20%
|
14.99
+1256.54%
|
1.11
+446.74%
|
0.20
|
| Cash Flow From Continuing Financing Activities |
|
9.86
-34.20%
|
14.99
+1256.54%
|
1.11
+446.74%
|
0.20
|
| Net Common Stock Issuance |
|
9.86
-33.93%
|
14.93
+1371.37%
|
1.01
+401.97%
|
0.20
|
| Proceeds From Stock Option Exercised |
|
0.00
-99.03%
|
0.06
-31.30%
|
0.09
|
0.00
|
| Changes In Cash |
|
-2.15
-152.67%
|
4.08
+22.58%
|
3.33
+110.50%
|
-31.72
|
| Beginning Cash Position |
|
19.19
+27.01%
|
15.11
+28.26%
|
11.78
-72.91%
|
43.50
|
| End Cash Position |
|
17.04
-11.20%
|
19.19
+27.01%
|
15.11
+28.26%
|
11.78
|
| Free Cash Flow |
|
-12.01
-10.12%
|
-10.91
+33.64%
|
-16.44
+39.05%
|
-26.97
|
| Common Stock Issuance |
|
9.86
-33.93%
|
14.93
+1371.37%
|
1.01
+401.97%
|
0.20
|
| Issuance Of Capital Stock |
|
9.86
-33.93%
|
14.93
+1371.37%
|
1.01
+401.97%
|
0.20
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-19 View
- 10-K2026-03-18 View
- 8-K2026-02-09 View
- 42025-11-19 View
- 42025-11-19 View
- 42025-11-19 View
- 8-K2025-11-14 View
- 10-Q2025-11-13 View
- 8-K2025-11-05 View
- 42025-11-04 View
- 42025-11-04 View
- 8-K2025-10-06 View
- 8-K2025-08-26 View
- 10-Q2025-08-14 View
- 8-K2025-08-12 View
- 8-K2025-06-17 View
- 8-K2025-06-09 View
- 8-K2025-05-20 View
- 10-Q2025-05-15 View
- 8-K2025-03-31 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|